🇺🇸 Fasenra in United States

FDA authorised Fasenra on 17 September 2024

Marketing authorisation

FDA — authorised 17 September 2024

  • Application: BLA761070
  • Marketing authorisation holder: ASTRAZENECA AB
  • Indication: Efficacy
  • Status: approved

The FDA granted marketing authorization to Fasenra, a product of AstraZeneca AB, on September 17, 2024. This authorization was based on a standard application (BLA761070) and is for the drug's approved efficacy indication. The exact indication and local brand name for Fasenra in the United States are not specified in the available information.

Read official source →

Fasenra in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in United States

Frequently asked questions

Is Fasenra approved in United States?

Yes. FDA authorised it on 17 September 2024.

Who is the marketing authorisation holder for Fasenra in United States?

ASTRAZENECA AB holds the US marketing authorisation.